What is Eribulin?
Eribulin is a drug that is commonly used to combat the metastatic breast cancer. Patients taking this medicine are usually in the late stages of the disease and have already had several rounds of chemotherapy. It was found that the drug increases the level of survival when other treatment failed. It is sold under the term Halaven ™. Its active ingredient is a substance called Halichondrin B, which occurs naturally in sea fungi, but is produced for eribulin. It is in the dynamic inhibitor of the microtubule. The typical cycle consists of two doses given to the patient in the first half of the 21 -day period. This cycle is repeated if the doctor prescribes the necessary. Depending on the patient's response, the dose may be changed to prevent side effects. Eribulin is an Erabulin served in a medical facility.
Patients should discuss their full history and use of medicines in a doctor before receiving eribulin. Some medicines may have a negative interaction unless a modified dose is prescribed. Many doctors BuDE also monitor the patient who also takes other medicines more carefully for side effects. The use of the drug can be too risky for patients who have or have a long QT syndrome.
The most common side effects of eribulin tend to be mild and need to be discussed with a doctor only if they do not disappear or if they become serious. They include a weak appetite, nausea and weight loss. Some patients also report atypical fatigue, weakness and headache. Hair loss and back, bone and joint pain were also reported.
Some potential side effects of eribulin are serious and should have immediate medical attention. These include breathing problems, unusually pale skin and irregular heart rhythm. Grade, tingling or burning sensation on the limbs can also be serious. Signs of infection such as fever and chills should also be reported.
have been conducted by studies to determine whether to be eRibulin prescribed for other uses. Most research focused on how other tumors affect the drug. Other conditions to heal include sarcoma, lung cancer and prostate cancer. Scientists have also studied the effects of the drug to see how it can be changed so that it can further increase life expectancy.